Sichuan Huiyu Pharmaceutical Co., Ltd.

688553

CNE100004ZT4

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 23:00:00 15/07/2024 BST			5-day change	1st Jan Change
11.93 ^CNY	-0.17%		+2.32%	-21.15%

06-28	Huiyu Pharmaceutical Unit Gets Nod to Market Three Cancer Drugs in Uzbekistan	MT
06-20	France Grants Marketing Approval for Huiyu Pharma's Osteoporosis Injection	MT

Tranche Update on Sichuan Huiyu Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 24, 2024.

May 23, 2024 at 05:00 pm

From April 1, 2024 to May 23, 2024, the company has repurchased 181,433 shares, representing 0.04% for CNY 2.44 million. With this, the company has completed the repurchase of 2,139,878 shares, representing 0.51% for CNY 30.01 million under the buyback announced on February 24, 2024.

Latest news about Sichuan Huiyu Pharmaceutical Co., Ltd.

Huiyu Pharmaceutical Unit Gets Nod to Market Three Cancer Drugs in Uzbekistan	06-28	MT
France Grants Marketing Approval for Huiyu Pharma's Osteoporosis Injection	06-20	MT
Tranche Update on Sichuan Huiyu Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 24, 2024.	05-23	CI
Sichuan Huiyu Pharmaceutical Co., Ltd.'s Equity Buyback announced on February 24, 2024, has closed with 2,139,878 shares, representing 0.51% for CNY 30.01 million.	05-22	CI
China Grants Drug Registration for Huiyu Pharma's Two Injectables	05-15	MT
Sichuan Huiyu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-26	CI
Sichuan Huiyu Pharmaceutical Gets Chinese FDA Nod for Methotrexate Anti-Tumor Injection	04-17	MT
Tranche Update on Sichuan Huiyu Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 24, 2024.	04-01	CI
Huiyu Pharma Unit Gets Libya's Marketing Approval for Cancer Drug	03-06	MT
Huiyu Pharma Gets China Registration Approval for Cancer Drug	03-05	MT
US FDA Grants New Drug Application to Huiyu Pharma's Cancer Injection	03-05	MT
Sichuan Huiyu Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 60 million worth of its shares.	02-23	CI
Sichuan Huiyu Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	02-23	CI
Sichuan Huiyu Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	02-22	CI
Three Drugs of Huiyu Pharma's Unit Gets Greenlight to Enter Egyptian Market	02-21	MT
Huiyu Pharma's Unit Gets Greenlight to Enter UK Market	02-19	MT
Huiyu Pharmaceutical's Subsidiary Administers First Patient for Tumor Drug Trial; Shares Drop 5%	02-05	MT
TYK Medicines, Inc. announced that it has received funding from Sichuan Huiyu Pharmaceutical Co., Ltd., CICC Capital Management Co., Ltd., Zhejiang Changxing Financial Holding Group Co., Ltd., and other investors	12-27	CI
Huiyu Pharma Passes US FDA Inspection	12-19	MT
Chengdu Houhan Technology Co., Ltd. and Beijing Houhong Technology Co., Ltd. agreed to acquire 49.9% stake in Sichuan Huiyu Yueying Pharmaceutical Technology Co., Ltd. from Sichuan Huiyu Pharmaceutical Co., Ltd. for CNY 16.6 million.	12-14	CI
Huiyu Pharmaceutical's Methotrexate for Injection Passes Regulatory Evaluation	11-24	MT
Sichuan Huiyu Pharma Gets Marketing Approval in Pakistan for Anticancer Drug	11-14	MT
Huiyu Pharmaceutical's Fulvestrant Injection Selected for China's Centralized Drug Procurement	11-08	MT
Sichuan Huiyu Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	27/10/23	CI
Huiyu Pharmaceutical's Unit Gets Nod to Trial HYP-2090PTSA Capsules	13/10/23	MT

Chart Sichuan Huiyu Pharmaceutical Co., Ltd.

Duration

Period

Chart Sichuan Huiyu Pharmaceutical Co., Ltd.

More charts

Company Profile

Sichuan Huiyu Pharmaceutical Co Ltd is a China-based company principally engaged in the research and development, production and sales of anti-tumor and injection drugs. The Companyâs products are mainly anti-tumor chemical injections, including pemetrexed disodium for injection, docetaxel injection, zoledronic acid injection, irinotecan hydrochloride injection, doxorubicin hydrochloride injection liquid and azacitidine for injection. The Company's products are mainly used in the clinical treatment of various adaptive diseases. The Company distributes its products both in the domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

22/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SICHUAN HUIYU PHARMACEUTICAL CO., LTD.	-21.15%	698M
ELI LILLY AND COMPANY	+61.53%	856B
NOVO NORDISK A/S	+38.95%	631B
JOHNSON & JOHNSON	-3.66%	359B
MERCK & CO., INC.	+15.06%	325B
ABBVIE INC.	+9.18%	297B
ROCHE HOLDING AG	+5.89%	234B
NOVARTIS AG	+16.53%	226B
AMGEN INC.	+15.67%	177B
PFIZER, INC.	+2.47%	165B